anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

130,501-130,560 of 319,975

filter-aware
173
The slide uses anecdotal evidence from social media to undermine the perceived value of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
174
The slide uses anecdotal evidence from Facebook groups to argue against the efficacy of a treatment by highlighting inconsistencies in user reports.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
175
The slide presents a skeptical analysis of patient/parent testimonials to undermine the perceived efficacy of a drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
176
The slide uses social media screenshots to undermine the credibility of a key proponent (Dr. Miller) by showing her own followers are skeptical of the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
177
The slide uses anecdotal evidence from Facebook groups to highlight patient dissatisfaction and side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
178
The slide uses direct quotes from Facebook group members to undermine the perceived efficacy and novelty of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
179
The slide uses anecdotal evidence from Facebook groups to illustrate a safety and compliance issue with the medication's delivery mechanism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
180
The slide uses screenshots of Facebook group discussions to highlight negative patient experiences.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
181
The slide uses screenshots of Facebook group discussions to highlight patient/caregiver concerns that may contradict or exceed official side effect reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
182
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
183
The slide uses a process diagram to illustrate the clinical trial flow, highlighting the transition from the failed C601 trial to the C602 withdrawal study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
184
The slide uses an excerpt from an FDA label to critique the clinical trial evidence supporting a drug's efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
185
The slide uses a red box to highlight the specific data points (weeks 12-16 of the withdrawal period) that the author claims are the basis for the company's efficacy argument.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
186
The slide uses a Q&A format to present evidence of potential trial manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
187
The slide uses a Q&A format to highlight potential data manipulation or questionable internal confidence in clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
188
The slide uses a 'quote-highlight' structure to emphasize specific allegations of misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
189
The slide uses a Q&A format to present qualitative evidence of investigator misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
190
The slide uses a 'show, don't tell' approach by presenting the actual questionnaire items to demonstrate their inherent subjectivity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
191
The slide uses direct quotes from investigators to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
192
The slide uses a Q&A format to present expert testimony regarding trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
193
The slide serves as a summary of deeper investigative findings regarding clinical trial data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
194
Focuses on trial design bias and potential data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
195
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
196
Includes chemical structures of Diazoxide and Choline to illustrate the 'salt' formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
197
Includes screenshots of FDA Orange Book data and the front page of US Patent 7,572,789.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
198
The slide lists four specific US patents to support the claim of weakness.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
199
The slide uses a red arrow to point from the summary list to the specific boxed text in the FDA label excerpt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
200
The slide serves as a product landscape overview to contrast current market offerings with the subject drug (Vykat).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
201
The slide uses a 'before-after' or 'comparison' logic to undermine the pricing power of the target company (Vykat) by highlighting readily available, cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
202
The slide uses a 'zoom-in' callout technique to highlight a specific claim in a scientific poster and then critiques the lack of supporting evidence for that claim.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
203
The slide uses a screenshot of a video to contrast the company's public claims with the underlying data source.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
204
The slide uses a forensic approach to discredit clinical data, specifically targeting the validity of a poster presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
205
The slide uses annotated charts to highlight alleged data manipulation in a clinical study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
207
The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
208
The slide uses a line chart to visually debunk a competitor's claim about drug absorption kinetics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
210
The slide uses two charts to illustrate why XR is ineffective for this specific drug profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
211
The slide uses a table to contrast the solubility of different diazoxide forms to undermine the company's rationale for their specific formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
212
The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
213
The slide uses a 'claim-refutation' structure to dismantle the target company's product differentiation narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
214
The slide uses molecular weight calculations to expose that DCCR is simply a salt form of diazoxide, implying the price premium is unjustified.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
215
The slide uses a Q&A format to validate the thesis that MDCalc is a key driver for off-label drug substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
216
Uses direct quotes from interviews to undermine the value proposition of the target company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
217
Uses expert quotes to debunk the necessity of the company's proprietary drug formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
218
Uses FDA label excerpts to highlight the contradiction between the drug's design and its actual usage/safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
219
The slide uses Q&A transcripts to highlight internal knowledge of safety risks and potential for generic substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
220
The slide uses a quote from a trial investigator to expose a potential safety oversight in study design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
221
The slide uses a Q&A transcript format to build a case against the drug's physical formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
222
Uses a combination of product imagery and user-generated content (Facebook post) to critique the competitor's dosing complexity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
223
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
224
The slide uses a Q&A transcript format to highlight negative sentiment from former employees.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
225
The slide uses direct quotes from an expert consultation to undermine the credibility of the drug's approval and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
226
The slide uses direct quotes from an ex-employee to build a case of corporate misconduct regarding clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
227
The slide uses a combination of a summary paragraph and a direct verbatim quote with highlighted sections.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
228
The slide uses a Q&A transcript format to highlight the alleged suppression of negative clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
229
The slide uses a Q&A format to highlight internal concerns regarding trial integrity and the potential for participant bias due to unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
230
The slide uses highlighted text to emphasize key criticisms (soft endpoints, cherry-picking, safety signals).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
231
The slide uses a Q&A transcript format to highlight potential safety data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
232
The slide uses a Q&A format to highlight potential corporate malfeasance regarding safety data reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit